Sudan ALMA Quarterly Report Quarter One, 2023



Scorecard for Accountability and Action



Malaria transmission in Sudan is low-to-moderate and occasionally epidemic. The annual reported number of malaria cases in 2021 was 3,960,655 with 1,679 deaths.

Metrics

Commodities Financed	
LLIN financing 2023 projection (% of need)	
Public sector RDT financing 2023 projection (% of need)	
Public sector ACT financing 2023 projection (% of need)	

Policy

Signed, ratified and deposited the AMA instrument at the AUC Malaria activities targeting refugees in Malaria Strategic Plan Malaria activities targeting IDPs in Malaria Strategic Plan Country Reporting Launch of Zero Malaria Starts with Me Campaign End Malaria Council and Fund Launched Resistance Monitoring, Implementation and Impact Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 Insecticide resistance monitored since 2015 and data reported to WHO National Insecticide Resistance Monitoring and Management Plan RDTs in stock (>6 months stock) LLIN/IRS campaign on track Operational LLIN/IRS coverage (% of at risk population) On track to reduce case mortality by ≥40% by 2021 (vs 2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of ICCM Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) Zels 0 Ptrane of children (0–14 years old) living with HIV who have access to antireroviral therapy (2021) Vitamin A Coverage 2021 (vaccination among 0-11 month olds) 0	Policy		
Plan Malaria activities targeting IDPs in Malaria Strategic Plan Country Reporting Launch of Zero Malaria Starts with Me Campaign End Malaria Council and Fund Launched End Malaria Council and Fund Launched Image: Council and Fund Launched Resistance Monitoring, Implementation and Impact Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 4 Insecticide resistance monitored since 2015 and data reported to WHO 1 National Insecticide Resistance Monitoring and Management Plan 1 RDTs in stock (>6 months stock) 1 LLIN/IRS campaign on track 1 Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 101 On track to reduce case mortality by ≥40% by 2021 (vs 2015) 101 Scale of Implementation of iCCM 1 Mass Treatment Coverage for Neglected Tropical Disease (NTD Index, %)(2021) 2 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 2 Vitamin A Coverage 2021 (2 doses) 0 0			
Plan Country Reporting Launch of Zero Malaria Starts with Me Campaign End Malaria Council and Fund Launched End Malaria Council and Fund Launched Image: Country Resistance Monitoring Conducted (2018-2020) and data reported to WHO Insecticide classes with mosquito resistance in representative sentimel sites confirmed since 2010 4 Insecticide resistance monitored since 2015 and data reported to WHO 4 National Insecticide Resistance Monitoring and Management Plan 4 RDTs in stock (>6 months stock) 4 LLIN/IRS campaign on track 100 Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 100 Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 3 Scale of Implementation of ICCM 10 Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 26 DPT3 coverage 2021 (vaccination among 0-11 month 84			
Me Campaign End Malaria Council and Fund Launched End Malaria Council and Fund Launched			
Resistance Monitoring, Implementation and Impact Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 Insecticide resistance monitored since 2015 and data reported to WHO National Insecticide Resistance Monitoring and Management Plan RDTs in stock (>6 months stock) ACTs in stock (>6 months stock) LLIN/IRS campaign on track Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of iCCM Mass Treatment Coverage (00 of at ropical Disease (NTD index, %)(2021) Vitamin A Coverage 2021 (2 doses) DT3 coverage 2021 (vaccination among 0-11 month			
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 4 Insecticide resistance monitored since 2015 and data reported to WHO 1 National Insecticide Resistance Monitoring and Management Plan 1 RDTs in stock (>6 months stock) 1 ACTs in stock (>6 months stock) 1 LLIN/IRS campaign on track 1 Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 1 Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 1 Scale of Implementation of iCCM 1 Mass Treatment Coverage to Neglected Tropical Disease (NTD index, %)(2021) 2 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 2 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	End Malaria Council and Fund Launched	Ļ	
data reported to WHO Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010 4 Insecticide resistance monitored since 2015 and data reported to WHO Insecticide Resistance Monitoring and Management Plan 4 RDTs in stock (>6 months stock) A 4 ACTs in stock (>6 months stock) 4 100 Operational LLIN/IRS coverage (% of at risk population) 100 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 100 100 On track to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Charack to reduce case mortality by ≥40% by 2021 (vs 2015) 100 100 Scale of Implementation of iCCM 100 100 100 Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 10 10	Resistance Monitoring, Implementation and Impact		
representative sentinel sites confirmed since 2010 4 Insecticide resistance monitored since 2015 and data 1 reported to WHO 1 National Insecticide Resistance Monitoring and Management Plan 1 RDTs in stock (>6 months stock) 1 ACTs in stock (>6 months stock) 1 LLIN/IRS campaign on track 1 Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 1 Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 1 Scale of Implementation of iCCM 1 Mass Treatment Coverage for Neglected Tropical Disease (NTD Index, %)(2021) 2 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 2 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84			
reported to WHO National Insecticide Resistance Monitoring and Management Plan RDTs in stock (>6 months stock) Image: Comparison of the stock o			4
Management Plan Image: Control of the stock of th			
ACTs in stock (>6 months stock) LLIN/IRS campaign on track Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of iCCM Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) Vitamin A Coverage 2021 (2 doses) DPT3 coverage 2021 (vaccination among 0-11 month			
LLIN/IRS campaign on track Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) 100 On track to reduce case mortality by ≥40% by 2021 (vs 2015) 100 On track to reduce case mortality by ≥40% by 2021 (vs 2015) 100 Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 19 Scale of Implementation of iCCM 10 Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 26 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	RDTs in stock (>6 months stock)		
Operational LLIN/IRS coverage (% of at risk population) 100 On track to reduce case incidence by ≥40% by 2021 (vs 2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of iCCM 0 Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 26 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	ACTs in stock (>6 months stock)		
On track to reduce case incidence by ≥40% by 2021 (vs 2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of ICCM Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) Vitamin A Coverage 2021 (2 doses) DPT3 coverage 2021 (vaccination among 0-11 month	LLIN/IRS campaign on track		
2015) On track to reduce case mortality by ≥40% by 2021 (vs 2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of ICCM Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 26 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	Operational LLIN/IRS coverage (% of at risk population)		100
2015) Tracer Indicators for Maternal and Child Health, NTDs and Covid 19 Scale of Implementation of ICCM Mass Treatment Coverage for Neglected Tropical Disease (NTD Index, %)(2021) Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month			
Scale of Implementation of ICCM Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021) 26 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84			
Mass Treatment Coverage for Neglected Tropical 0 Disease (NTD index, %)(2021) 0 Estimated % of children (0–14 years old) living with HIV 26 Who have access to antiretroviral therapy (2021) 0 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	Tracer Indicators for Maternal and Child Health, NTDs and	d Co	vid 19
Disease (NTD index, %)(2021) U Estimated % of children (0–14 years old) living with HIV 26 Who have access to antiretroviral therapy (2021) 0 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84	Scale of Implementation of iCCM		
who have access to antiretroviral therapy (2021) 25 Vitamin A Coverage 2021 (2 doses) 0 DPT3 coverage 2021 (vaccination among 0-11 month 84			0
DPT3 coverage 2021 (vaccination among 0-11 month			26
	Vitamin A Coverage 2021 (2 doses)		0
			84

Key



Target achieved or on track Progress but more effort required Not on track No data Not applicable



Malaria

Global Fund Allocation

The Global Fund announced that Sudan will receive US\$151.2 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on Sudan's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and previous disbursements. For Sudan this is calculated at US\$ 118.1 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. Sudan is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress. The Global Fund resources are especially important in the current resource constrained environment. The ongoing economic crisis, increased costs of doing business, and the need to introduce newer more expensive commodities to address insecticide and drug resistance mean that countries may experience shortfalls in sustaining their life-saving malaria essential services.

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, Sudan has procured sufficient LLINs to achieve operational vector control coverage of the targeted at-risk population. The country has carried out insecticide resistance monitoring since 2015 and has reported the results to WHO and has completed the insecticide resistance testing since 2018 and the data have been reported to WHO. The country. Sudan has also scaled up the implementation of iCCM.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, Sudan has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard, although the scorecard is not yet shared on the ALMA Scorecard Hub. The country should consider establishing an End Malaria Council and Fund to enhance domestic resource mobilization and multi-sectoral action.

Impact

The annual reported number of malaria cases in 2021 was 3,960,655 with 1,679 deaths.

Key Challenges

- Insecticide resistance threatens vector control.
- Gaps in funding for IRS.

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Investigate and address the reasons for the increase in estimated malaria incidence between 2015 and 2021	Q4 2023		The following are some of the factors that might have contributed to the despite that it is impossible to the increase in estimated malaria incidence in Sudan between 2015-2021: A very weak malaria programme both in structure and in function at national and states level to adequately respond to malaria interventions; Insufficient financial resources and the country's overall economic situation resulting in the deterioration of basic infrastructures i.e. broken water pipes leading to increased risk of malaria transmission in urban areas – including weak intersectoral collaboration; Poor data quality and insufficient use of available data for high resolution to appropriately target malaria interventions; Frequent outbreaks of other VBDs and large influx of refugees from neighboring countries and IDPs have overstretched the performance of the health system overall, and that of the malaria programme in particular; Widespread malaria vector resistance to insplement IRS and continuous distribution of LLINs. Consideration will be given towards the scaling up and use of next generation nets (IG2) and frequent stock- outs of diagnostics and antimalarials and poor knowledge and adherence to malaria diagnosis and treatment protocols. These issues and challenges are being discussed with senior management of the Ministry of Health as key recommendations from the current MPR
Policy	Sign, ratify and deposit the AMA instrument at the AUC	Q1 2023		No progress reported

Previous Key Recommended Actions

RMNCAH and NTDs

Progress

The country has enhanced tracking and accountability mechanisms with the development of a Reproductive, Maternal, Newborn, Child and Adolescent Health Scorecard.

Progress in addressing Neglected Tropical Diseases (NTDs) in Sudan is measured using a composite index calculated from preventive chemotherapy coverage achieved for lymphatic filariasis, onchocerciasis, schistosomiasis, soil transmitted helminths and trachoma. In 2021, preventive chemotherapy coverage was 3% for trachoma and zero for lymphatic filariasis, onchocerciasis, schistosomiasis and soil transmitted helminths. Overall, the NTD preventive chemotherapy coverage index for Sudan in 2021 is 0 which

represents a decrease compared with the 2020 index value (3).

Objective	Action Item	Suggested completion timeframe	Progres s	Comments - key activities/accomplishments since last quarterly report
NTDs	Work to increase preventive chemotherapy coverage for all NTDs, lymphatic filariasis, onchocerciasis schistosomiasis, soil transmitted helminths and trachoma to reach WHO targets	Q4 2023		Deliverable not yet due
Optimise quality of care	Address the falling coverage of vitamin A	Q4 2022		The country significantly increased the coverage of vitamin A in 2021 during the first round, but distribution was disrupted by COVID-19 for the second round and so coverage of the required 2 doses remains low. The Vitamin A supplementation programme has been constrained in 2022 as Sudan was declared Polio free and phased out from campaigns. Accordingly, the country planned for to reach 50% (approx. 4 million 6-59 children) of the 2022 annual target (approx. 7 million 6-59 months old children) with two doses through the routine, however, only 600, 000 children 6-50 months were reached with one dose in second semester of 2022 and the remainder has rolled over into 2023. Taking advantage of the upcoming (18 March 2023) Polio outbreak response campaign, the country is planning to reach 100% of the 2023 annual target with the first dose. The second dose of 2023 will be administrated through the routine with an ambition to reach only 50% of the 2023 annual target with the second dose of Vitamin A supplementation for 2023

Previous Key Recommended Actions

Sudan has responded positively to the RMNCAH recommended action addressing low coverage of postnatal care and coverage of ARTs and continues to track progress as this action is implemented.

Key

Action achieved
Some progress
No progress
Deliverable not yet due